CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilisation in multiple myeloma

被引:24
作者
Dyson, PG
Horvath, N
Joshua, D
Barrow, L
Van Holst, NG
Brown, R
Gibson, J
To, LB
机构
[1] Hanson Ctr Canc Res, Inst Med & Vet Sci, Div Haematol, Adelaide, SA, Australia
[2] Royal Adelaide Hosp, Bone Marrow Transplant Unit, Adelaide, SA 5000, Australia
[3] Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW 2050, Australia
关键词
CD34(+) selection; multiple myeloma; PBSC autotransplantation;
D O I
10.1038/sj.bmt.1702408
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
A potential problem of autologous transplantation in the treatment of multiple myeloma (MM) is the infusion of tumor cells, CD34(+) selection has been used to purge autografts in MM and it is also possible to reduce tumour cell contamination of autografts by cytotoxic drug therapy prior to peripheral blood stem cell (PBSC) collection. To evaluate the effectiveness of a protocol combining multiple cycles of high-dose therapy and CD34(+) selection to reduce tumour contamination of PBSC autografts, 34 MM patients were entered on a treatment schedule comprising two sequential cycles of mobilisation, CD34(+) selection, and transplantation following high-dose therapy. In the second cycle of mobilisation there was a five-fold reduction in tumour contamination of the stem cell harvest (0.5 x 10(6)/kg) compared with the first cycle (2.5 x 10(6)/kg). In the 97 CD34(+) selection procedures performed a median of 185 x 10(8) mononuclear cells (R-INC) were processed yielding a median of 0.98 x 10(8) CD34(+)-enriched cells. CD34(+) cells were enriched 68-fold from 1.3% to 88.6%. The median yield of CD34(+) cells was 42.2%. Following CD34(+) selection the tumour cell contamination of the leukapheresis product was reduced by a median of 2.7 logs. This study demonstrates that in multiple myeloma a significant reduction ill the malignant contamination of stem cell autografts can be achieved by combining the in vivo purging effect of cytotoxic therapy with in vitro purging by CD34(+) selection.
引用
收藏
页码:1175 / 1184
页数:10
相关论文
共 39 条
[1]  
ANDERSON KC, 1993, BLOOD, V82, P2568
[2]   Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells [J].
Beguin, Y ;
Baudoux, E ;
Sautois, B ;
Fraipont, V ;
Schaaf-Lafontaine, N ;
Pereira, M ;
Paulus, JM ;
Sondag, D ;
Fillet, G .
TRANSFUSION, 1998, 38 (02) :199-208
[3]   Should we purge? [J].
Bensinger, WI .
BONE MARROW TRANSPLANTATION, 1998, 21 (02) :113-115
[4]   IN MULTIPLE-MYELOMA, CLONOTYPIC B-LYMPHOCYTES ARE DETECTABLE AMONG CD19(+) PERIPHERAL-BLOOD CELLS EXPRESSING CD38, CD56, AND MONOTYPIC IG LIGHT-CHAIN [J].
BERGSAGEL, PL ;
SMITH, AM ;
SZCZEPEK, A ;
MANT, MJ ;
BELCH, AR ;
PILARSKI, LM .
BLOOD, 1995, 85 (02) :436-447
[5]   THE BONE-MARROW OF MULTIPLE-MYELOMA PATIENTS CONTAINS B-CELL POPULATIONS AT DIFFERENT STAGES OF DIFFERENTIATION THAT ARE CLONALLY RELATED TO THE MALIGNANT PLASMA-CELL [J].
BILLADEAU, D ;
AHMANN, G ;
GREIPP, P ;
VANNESS, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1023-1031
[6]   Diagnosis, prognosis, and standard treatment of multiple myeloma [J].
Boccadoro, M ;
Pileri, A .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (01) :111-&
[7]   GENE-MARKING TO TRACE ORIGIN OF RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRENNER, MK ;
RILL, DR ;
MOEN, RC ;
KRANCE, RA ;
MIRRO, J ;
ANDERSON, WF ;
IHLE, JN .
LANCET, 1993, 341 (8837) :85-86
[8]  
BROUN ER, 1994, EXP HEMATOL, V22, P775
[9]   IDIOTYPIC OLIGONUCLEOTIDE PROBES TO DETECT MYELOMA CELLS BY MESSENGER-RNA IN-SITU HYBRIDIZATION [J].
BROWN, R ;
LUO, XF ;
GIBSON, J ;
MORLEY, A ;
SYKES, P ;
BRISCO, M ;
JOSHUA, D .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (01) :113-118
[10]   Purging: The separation of normal from malignant cells for autologous transplantation [J].
Champlin, R .
TRANSFUSION, 1996, 36 (10) :910-918